Email updates

Keep up to date with the latest news and content from Genome Medicine and BioMed Central.

Highly Accessed Editorial

Proteomics: improving biomarker translation to modern medicine?

Paul C Guest1*, Michael G Gottschalk1 and Sabine Bahn12

Author Affiliations

1 Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK

2 Department of Neuroscience, Erasmus Medical Centre, Rotterdam, The Netherlands

For all author emails, please log on.

Genome Medicine 2013, 5:17  doi:10.1186/gm421

Published: 27 February 2013

First paragraph (this article has no abstract)

Biomarkers are defined as 'measurable characteristics that reflect physiological, pharmacological, or disease processes' according to the European Medicines Agency [1]. The ideal platforms for biomarker discovery include genomic, transcriptomic, proteomic, metabonomic and imaging analyses. However, most biomarkers used in clinical studies are based on proteomic applications as the majority of current drug targets are proteins, such as G protein-coupled receptors, ion channels, enzymes and components of hormone signaling pathways [2]. Furthermore, linking the results of biomarker studies using protein-protein interaction approaches can assist in systems biology approaches and could lead to hypothesis generation and identification of new drug targets [3].